Inotuzumab (powder)
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin. Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][2][3][4]. x
Product Specifications
CAS Number
1660159-36-3
Product Name Alternative
Humanized Anti-CD22 Recombinant Antibody (powder)
UNSPSC
12352203
Target
ADC Antibody; Apoptosis; CD22
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Immunology/Inflammation
Field of Research
Cancer
Smiles
[Inotuzumab(powder)]
Molecular Weight
(146.48 kDa)
References & Citations
[1]Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9.|[2]Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3 (1) :96-104. |[3]Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137 (19) :2657-2661.|[4]Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18 (5) :1101-1116.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TP305918M 100 µg
HMG1 (HMGB1) (NM_002128) Human Recombinant Protein
Sign In for Pricing
View Details